🔎 Trials Near Me

መነሻ › አልሰራቲቭ ኮላይቲስ › ኢሊኖይ › Chicago

በChicago፣ IL ለአልሰራቲቭ ኮላይቲስ የሚደረጉ ክሊኒካዊ ጥናቶች

ለአልሰራቲቭ ኮላይቲስ የሚደረጉ 15 ጥናቶች በChicago እና በአካባቢው ባሉ ቦታዎች (በወደ 30 ማይል ውስጥ) ተሳታፊዎችን እየፈለጉ ነው። ማን መሳተፍ እንደሚችል እና የጥናት ቡድኑን እንዴት መገናኘት እንደሚቻል ለማየት ጥናቱን ክፈቱ።

Official study text (English)

ለጥናት ተሳታፊዎችን እየፈለጉ ነው? በዚህ ገጽ ላይ በ$99 ለ30 ቀናት ያስቀምጡት →

A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • University of Chicago Medical Center /ID# 271588, Chicago
እድሜ ከ2 እስከ 17 · ሁሉም ጾታዎች · የተሻሻለው በ30 ሴፕቴ 2026 · NCT07071519

A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Northwestern University, Chicago
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ30 ሴፕቴ 2026 · NCT06598943

A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Site 038, Chicago
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ29 ሴፕቴ 2026 · NCT07012395

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • University of Chicago Medical Center, Chicago
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT06979336

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • Rush University Medical Center, Chicago
እድሜ ከ18 እስከ 70 · ሁሉም ጾታዎች · የተሻሻለው በ24 ሴፕቴ 2026 · NCT06937086

LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Northwestern University, Chicago
እድሜ ከ18 እስከ 80 · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT07186101

A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Rush University Medical Center, Chicago
እድሜ ከ18 እስከ 80 · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT07483073

LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Northwestern University, Chicago
  • Rush University Medical Center, Chicago
እድሜ ከ18 እስከ 80 · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT07415044

A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

ተሳታዮችን በመፈለግ ላይደረጃ 4
  • University of Chicago Medicine, Chicago
እድሜ ከ18 እስከ 65 · ሁሉም ጾታዎች · የተሻሻለው በ21 ሴፕቴ 2026 · NCT06095128

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • Rush University Medical Center - Site Number: 8400015, Chicago
እድሜ ከ16 እስከ 80 · ሁሉም ጾታዎች · የተሻሻለው በ20 ኦገስ 2026 · NCT07184996

Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission

ተሳታዮችን በመፈለግ ላይ
  • University of Chicago Medicine, Chicago
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ7 ኦገስ 2026 · NCT05230173

An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis

ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
  • Feinberg School of Medicine Northwestern University, Chicago
  • Rush University Medical Center, Chicago
እድሜ ከ18 እስከ 64 · ሁሉም ጾታዎች · የተሻሻለው በ9 ጁላይ 2026 · NCT06398626

A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • University of Chicago Medical Center, Chicago
እድሜ ከ12 እስከ 17 · ሁሉም ጾታዎች · የተሻሻለው በ8 ጁላይ 2026 · NCT05287126

Selenium Supplementation in Moderate-Severely Active Ulcerative Colitis Patients Treated With Advanced Therapies

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Northwestern University, Chicago
እድሜ ከ18 እስከ 85 · ሁሉም ጾታዎች · የተሻሻለው በ22 ሜይ 2026 · NCT07427017

STOP-UC: De-escalation of Therapy in Patients With Ulcerative Colitis With Histological Remission

ተሳታዮችን በመፈለግ ላይ
  • University of Chicago, Chicago
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ6 ኤፕሪ 2026 · NCT06693310

በሌሎች ከተሞች ለአልሰራቲቭ ኮላይቲስ የሚደረጉ ጥናቶች

በChicago ውስጥ ያሉ ሌሎች ጥናቶች

ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።